MedTrace Logo

Image Guided RFA/MWA/CRYO of RCC Biomarker Profile Study

NCT04392076 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2020-05-19

No results posted yet for this study

Summary

Often kidney cancer is diagnosed when the tumour is small and hasn't spread. Rather than major surgery to remove the whole kidney, image-guided ablation involving heat (microwave or radiofrequency) or freezing (cryotherapy) is often used to destroy the tumour using minimal invasive technique with much less risk and discomfort. Limited evidence suggests that ablation also activates the immune system which may help in fighting the cancer. We will investigate the immune and other changes by analysing blood samples from patients before and after ablation. Understanding this will help in designing more effective new treatments combining ablation with biological therapies.

Conditions

  • Renal Cancer

Interventions

PROCEDURE

Image Guided Ablation

Image Guided Ablation with RFA, MWA or CRYO of Renal Cancer

Sponsors & Collaborators

  • The Leeds Teaching Hospitals NHS Trust

    collaborator OTHER

  • University of Leeds

    lead OTHER

Principal Investigators

  • Tze Min Wah, PhD MBchB · Leeds Teaching Hospitals Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04392076 on ClinicalTrials.gov